LDLR and Hypercholesterolemia: LDL-receptor protein is degraded by proprotein convertase subtilisin or kexin type 9 (PCSK9): LoF mutations in PCSK9 protect against CVD, whereas GoF mutations are associated with hypercholesterolemia and accelerated CVD57–59, demonstrating the critical role of this pathway.